EMBLAVEO for complicated intra-abdominal infections in adults caused by designated susceptible gram-negative microorganisms.

Feb 7, 2025 · EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, …

EMBLAVEO, in combination with metronidazole, is indicated in patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal …

EMBLAVEO is a combination of aztreonam, a monobactam antibacterial, and avibactam, a beta-lactamase inhibitor, that when used in combination with metronidazole, is indicated in patients …

Apr 22, 2024 · EMBLAVEO ® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by …

Mar 22, 2024 · Emblaveo is an antibiotic used in adults to treat: Complicated (difficult to treat) intra-abdominal (belly) infections; Hospital-acquired pneumonia (an infection of the lungs that …

Feb 9, 2025 · Overview: Emblaveo is an intravenous (IV) antibiotic that is used for certain infections in the abdomen or stomach area caused by bacteria. Common side effects include …

Feb 13, 2025 · What Is Emblaveo? Emblaveo (aztreonam and avibactam) is a combination of a monobactam antibacterial, and a beta-lactamase inhibitor, that when used in combination with …

Emblaveo is a medication that combines two components: aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor that protects aztreonam from serine β-lactamase …

Feb 7, 2025 · Emblaveo is supplied in a single-dose vial as a lyophilized powder containing 1.5g of aztreonam and 0.5g of avibactam that requires reconstitution and dilution prior to IV …